Get started
Author

Víctor Cervera-Carrascón

Observed names: Cervera-Carrascon, Victor, V. Cervera Carrascon, V. Cervera-Carrascon, Victor Cervera-Carrascon, Victor Cervera‐Carrascon, Víctor Cervera Carrascón, Víctor Cervera-Carrascon, Víctor Cervera‐Carrascon
ORCID: 0000-0001-6684-3666
Observed ORCID: 0000-0001-6684-3666
OpenAlex ID: A5080358452
TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
2018 · V. Cervera-Carrascon, M. Siurala, et al. · OncoImmunology · 109
PDF
Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
2020 · João Manuel Santos, Camilla Heiniö, et al. · Journal for ImmunoTherapy of Cancer · 62
PDF
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
2018 · Riikka Havunen, João M. Santos, et al. · Molecular Therapy — Oncolytics · 62
PDF
Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy
2018 · João Manuel Santos, Víctor Cervera-Carrascon, et al. · Molecular Therapy · 55
PDF
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma
2016 · Mikko Siurala, Riikka Havunen, et al. · Molecular Therapy · 52
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer
2022 · James H. A. Clubb, Tatiana V. Kudling, et al. · Frontiers in Immunology · 49
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
2021 · Riikka Havunen, Riikka Kalliokoski, et al. · Cells · 44
PDF
TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling
2020 · Camilla Heiniö, Riikka Havunen, et al. · Cells · 44
PDF
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
2020 · Victor Cervera-Carrascon, Dafne C.A. Quixabeira, et al. · Molecular Therapy — Oncolytics · 44
PDF
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial
2025 · Matthew Stephen Block, James Hugo Armstrong Clubb, et al. · Nature Communications · 39
PDF
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control
2021 · Dafne C. A. Quixabeira, Sadia Zafar, et al. · Frontiers in Immunology · 37
PDF
Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al. · Clinical Cancer Research · 36
PDF
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression
2022 · Tatiana V. Kudling, James H.A. Clubb, et al. · OncoImmunology · 36
Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
2021 · Joao Santos, Camilla Heiniö, et al. · Cells · 36
PDF
CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy
2018 · Sadia Zafar, Suvi Sorsa, et al. · OncoImmunology · 36
PDF
Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
2019 · Victor Cervera-Carrascon, Riikka Havunen, et al. · Expert Opinion on Biological Therapy · 32
PDF
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
2020 · Victor Cervera-Carrascon, Dafne C.A. Quixabeira, et al. · OncoImmunology · 31
Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples
2020 · Sadia Zafar, Saru Basnet, et al. · Human Gene Therapy · 29
PDF
A novelin silicoframework to improve MHC-I epitopes and break the tolerance to melanoma
2017 · Cristian Capasso, Aniket Magarkar, et al. · OncoImmunology · 29
PDF
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors
2024 · Elise Jirovec, Dafne C. A. Quixabeira, et al. · Journal of Experimental & Clinical Cancer Research · 28
PDF
Enhanced Stability and Bioactivity of Natural Anticancer Topoisomerase I Inhibitors through Cyclodextrin Complexation
2021 · Víctor González-Ruiz, Ángel Cores, et al. · Pharmaceutics · 28
PDF
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer
2023 · Tatiana V. Kudling, James H.A. Clubb, et al. · OncoImmunology · 25
PDF
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1
2021 · Victor Cervera-Carrascon, Dafne C. A. Quixabeira, et al. · Frontiers in Immunology · 25
PDF
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine
2024 · Saru Basnet, Mirte Van der Heijden, et al. · Molecular Therapy · 23
Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes
2020 · Sadia Zafar, Dafne Carolina Alves Quixabeira, et al. · Cancer Gene Therapy · 22
PDF
Works count: 119
Citation count: 1,271
H-index: 23
I10-index: 38
Year
Topic
Type